Garbe Edeltraut
University Professor of Clinical Epidemiology, Bremen Institute for Prevention Research and Social Medicine, Bremen, Germany.
Expert Opin Drug Saf. 2007 May;6(3):323-35. doi: 10.1517/14740338.6.3.323.
Acute agranulocytosis is a rare, potentially life-threatening condition, which is attributable to drugs in > 70% of cases. Agranulocytosis is characterised by a peripheral neutrophil count < 0.5 x 10(9)/l. It often manifests with a severe sore throat, but isolated fever, pneumonia or septicaemia are not uncommon. Agranulocytosis may be caused by many drugs. High-risk drugs include antithyroid drugs, clozapine, ticlopidine, sulfasalazine, dipyrone, trimethoprim/sulfamethoxazole, carbamazepine and probably rituximab. Suspect drugs should be stopped immediately. In febrile patients, blood cultures and, where indicated, site-specific cultures should be obtained and treatment with empirical broad spectrum antibiotics started. Haematopoietic growth factors should be considered in patients with poor prognostic factors (e.g., a neutrophil count < 0.1 x 10(9)/l), severe clinical infection or severe underlying disease or comorbidity. Case fatality has decreased to ~ 5% in recent years, probably owing to improved intensive care treatment and increased alertness of physicians to this severe adverse reaction.
急性粒细胞缺乏症是一种罕见的、可能危及生命的疾病,70%以上的病例可归因于药物。粒细胞缺乏症的特征是外周血中性粒细胞计数<0.5×10⁹/L。它常表现为严重的咽痛,但单纯发热、肺炎或败血症也并不少见。粒细胞缺乏症可能由多种药物引起。高危药物包括抗甲状腺药物、氯氮平、噻氯匹定、柳氮磺胺吡啶、安乃近、甲氧苄啶/磺胺甲恶唑、卡马西平,可能还有利妥昔单抗。应立即停用可疑药物。对于发热患者,应进行血培养,并在必要时进行特定部位的培养,同时开始使用经验性广谱抗生素治疗。对于预后不良因素(如中性粒细胞计数<0.1×10⁹/L)、严重临床感染或严重基础疾病或合并症的患者,应考虑使用造血生长因子。近年来,病死率已降至约5%,这可能归功于重症监护治疗的改善以及医生对这种严重不良反应的警惕性提高。